The Scientist

» biotech

Most Recent

image: Hearing Help

Hearing Help

By | September 1, 2015

For decades, the only remedies for hearing loss were devices such as hearing aids or cochlear implants. Now, the first pharmaceutical treatments may be on the way.  

2 Comments

image: TS Live: Pharma Feast

TS Live: Pharma Feast

By | August 26, 2015

A sampling of the biggest acquisitions reshaping the life sciences industry in 2015

0 Comments

image: FDA Approves 3-D–Printed Drug

FDA Approves 3-D–Printed Drug

By | August 4, 2015

The US Food and Drug Administration green lights the first medicine produced by a 3-D printer for use in the human body.

1 Comment

image: Tasty Visuals

Tasty Visuals

By | June 23, 2015

A newly approved visual aid translates the appearance of objects to electrical stimulation on the tongue.

0 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Custom Creatures?

Custom Creatures?

By | January 6, 2015

San Francisco-based biotech wants to see its technology applied for inventing new organisms.

0 Comments

image: Incentivizing Breakthroughs

Incentivizing Breakthroughs

By | December 1, 2014

With scientific funding on shaky ground, big-dollar competitions offer a new way for life-science innovators to bring their ideas to fruition.

1 Comment

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

0 Comments

image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

0 Comments

image: Merck Snaps Up Biotech for $3.85B

Merck Snaps Up Biotech for $3.85B

By | June 10, 2014

The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech